Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Gubra reveals early data for once-weekly obesity asset
Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with most adverse events "mild" and "transient."
Gabrielle Masson
Nov 13, 2024 5:56pm
AstraZeneca still 'playing to win' in obesity, execs say
Nov 4, 2024 11:49am
In $285M deal, Novo taps Ascendis to help create monthly GLP-1
Nov 4, 2024 8:43am
Viking oral obesity med posts 6.8% weight loss for highest dose
Nov 4, 2024 7:30am
Metsera allies with Amneal to lock down GLP-1 supply
Oct 1, 2024 6:01am
Rivus posts data to back up muscle-sparing obesity drug claims
Sep 30, 2024 11:09am